Stock Ratings / Health Care / TRVI / insiders

XERS (62) ZYME (47) GENB (61) BRVE (47) ⌘ Pro Terminal →

Trevi Therapeutics Inc. (TRVI) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$13.81 +2.15% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Trevi Therapeutics Inc. (TRVI) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.97B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRVI)Realized 20D OHLCV Swing Band: ±11.2%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TRVI Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TRVI)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TRVI. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRVI)

✓Walkthrough of TRVI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRVI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.36%▼ DESCENDING CHANNEL

2026-10-30O $13.52H $13.91L $13.44C $13.81VOL 1.73M

RES: $17.90SUP: $11.02SMA50: $14.69SMA200: $14.34

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRVI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRVI Butterfly Map → + Track TRVI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRVI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRVI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRVI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRVI)

Health Care Rank #661 of 1016 ⚔️ XERS vs TRVI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRVI vs. XERS, ZYME, GENB, BRVE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Trevi Therapeutics Inc. (TRVI) ranks #661 by composite RQD confidence (39/100, grade D-) and #266 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, TRVI leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with TRVI at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRVI ACTIVE Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	Benchmark Subject
XERS Xeris Biopharma Holdings Inc.	C	62/100	—	—	16.0%	+1.03%	$1.96B	/xers-vs-trvi →
ZYME Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	/zyme-vs-trvi →
GENB Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	/genb-vs-trvi →
BRVE Braveheart Bio Inc.	D	47/100	—	—	—	-2.62%	$1.91B	/brve-vs-trvi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001563880

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trevi Therapeutics Inc. (TRVI) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$42.8M, operating cash flow of -$42.1M, and free cash flow of -$42.1M (-10.0% YoY). On the balance sheet, TRVI closed FY2025 with $193.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$42.8M	-$42.1M	-$42.1M	$193.4M	—
FY2024 (FY)	2024-12-31	$0	-$47.9M	-$38.3M	-$38.3M	$110.9M	—
FY2023 (FY)	2023-12-31	$0	-$29.1M	-$31.7M	-$31.7M	—	—

3. TRVI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRVI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Trevi Therapeutics Inc. (NASDAQ: TRVI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $13.81 (+2.15% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TRVI ranks #661 in composite RQD confidence.

How does TRVI compare to XERS and ZYME in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TRVI carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -23.7%. By comparison, XERS (Xeris Biopharma Holdings Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC 16.0%, cap $1.96B) and ZYME (Zymeworks Inc.) posts a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B). Among the 5-stock peer group, TRVI leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRVI?

Per TRVI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001563880), Trevi Therapeutics Inc. generated $0 in revenue, -$42.8M in net income, and -$42.1M in free cash flow against $193.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRVI trading relative to its 50-day, 200-day, and 52-week technical levels?

TRVI last traded at $13.81 (+2.15% on volume of 1,345,331 shares), positioning the stock -5.99% below its 50-day simple moving average ($14.69) and -3.70% below its 200-day simple moving average ($14.34). Across its 52-week range of $9.82 to $20.22, TRVI sits at the 38.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($12.26 to $15.36).

TRVI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TRVI insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TRVI leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: TRVI RQD Cockpit TRVI 12M Forecast TRVI Earnings & Move TRVI Dividends & DRIP TRVI Insiders & 13F TRVI Whale Options TRVI Profit Sankey TRVI News & Why